A new international study reveals that GLP-1 receptor agonists—commonly used for weight loss—may significantly reduce the risk of dementia in people with type 2 diabetes, outperforming metformin.

Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.

Common medicines, including diabetes, cancer, and antiviral drugs, may offer new hope in slowing dementia. UK researchers, including a team from the University of Cambridge, have uncovered strong ...

GLP-1s - which mimic the effects of the hormone that stimulates insulin release, suppressing glucagon, and slowing gastric emptying - also have a range of other benefits.

FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway found a 45% lower risk in ...

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.

Newly published research claims those taking GLP-1 jabs are at a 37 percent lower risk of dementia than those on the ...

A new scientific study has found that weight loss jabs such as Mounjaro and Ozempic can help protect against serious health ...